Supernus Pharmaceuticals announced that Oxtellar XR (oxcarbazepine extended-release) tablets are now available. Oxtellar XR is an antiepileptic indicated for adjunctive therapy in the treatment of partial seizures in adults and in children 6–17 years of age.

Oxcarbazepine produces blockade of voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminution of propagation of synaptic impulses.

Oxtellar XR is available in 150mg, 300mg, and 600mg extended-release tablets in 100-count bottles.

For more information call (301) 838-2500 or visit www.oxtellarxr.com